TALAPRO-2: Toxicities and Treatment Duration

In the second part of this peer-to-peer discussion at the 2023 Uromigos Live & Unplugged event, Tanya Dorff, MD, City of Hope, and Neeraj Agarwal, MD, University of Utah, summarize the toxicities associated with talazoparib for patients with metastatic castration-resistant prostate cancer.

They also provide recommendations for monitoring adverse events in the first few months of treatment, as well as treatment dosage and duration considerations.

View the other parts of this discussion, including Talazoparib Plus Enzalutamide: TALAPRO-2 Results and Subset Analyses, How Has TALAPRO-2 Changed the Standard of Care for First-Line mCRPC With HRR Mutations, and Importance of Genomic Testing for Patients With Metastatic Prostate Cancer.